Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology

Core Insights - Anixa Biosciences has received a Notice of Allowance for a patent from the Korean Ministry of Intellectual Property for its breast cancer vaccine technology, marking the first Korean patent for this platform [1] - The patent, titled "Vaccine Adjuvants and Formulations," provides composition of matter protection and is expected to enhance Anixa's global intellectual property portfolio [1] - The company aims to leverage this patent to pursue international commercialization opportunities and potential partnerships with larger pharmaceutical firms [1] Patent and Technology - The newly allowed patent reinforces Anixa's leadership in cancer immunotherapy and complements existing patents in the United States and other jurisdictions [1] - The breast cancer vaccine technology is based on immunizing against human -lactalbumin, a protein associated with lactation, which is aberrantly expressed in certain breast cancer types [1] - Anixa's vaccine has shown promising results in a Phase 1 clinical trial, meeting all major primary endpoints and generating immune responses in 74% of participants [1] Market Context - Breast cancer incidence rates are rising in South Korea, with a notable trend of earlier onset compared to Western nations [1] - Breast cancer remains the most commonly diagnosed cancer among women globally, and there are currently no approved vaccines for its prevention [1] - Anixa's approach aims to transform cancer prevention strategies, particularly for aggressive forms like triple-negative breast cancer [1] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy developed in collaboration with Moffitt Cancer Center [1] - The company partners with renowned research institutions to develop vaccines targeting various cancers, including breast and ovarian cancer [1] - Anixa's business model emphasizes collaboration at all stages of development, allowing for the exploration of emerging technologies in complementary fields [1]